© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.
December 03, 2021
Guselkumab is the first and only selective interleukin inhibitor therapy in the US that's approved for both moderate-severe plaque psoriasis and active psoriatic arthritis regardless of prior TNFi exposure.
November 19, 2021
The biologic has shown promise in the management of both plaque psoriasis and psoriatic arthritis.
November 15, 2021
Dr. Elewski hopes that in the future more clinicians will prescribe biologics such as secukinumab and etancercept for the treatment of psoriasis.
Certain biologics such as infliximab have aided psoriasis patients in the mitigation of symptoms from the COVID-19 virus.
Dr. Elewski speaks of the safety and efficacy of several new and developing therapies, including bimekizumab treatment which has yet to be approved in the United States.
October 29, 2021
Investigators stated that prolonged maintenance dosing of the monoclonal antibody was preferred by affected patients.
Investigators reported that the efficacy of the medication is supported by a high safety profile, with fleeting and limited adverse events recorded.
October 25, 2021
Investigators reported that a higher proportion of participants in the abatacept group relapsed between weeks 12 and 40 compared to participants in the ustekinumab group.
October 24, 2021
The rates of adverse events was similar across all 4 indications in comparison to the placebo group.
October 18, 2021
Travel issues related to COVID-19 were responsible for the delay in the approval of the Biologics License Application.